Objective: To identify the haematological causes of thrombocytopenia in children admitted at a tertiary care hospital.
Methods: The prospective, descriptive study was carried out at the Aga Khan University Hospital, Karachi, from September 3, 2009 to March 3, 2010, and comprised children between one month and 14 years of age with platelet count less than15000. After reviewing the record, a questionnaire was filled and data was analysed using SPSS 15.
Results: Out of 108 patients in the study, 69(64%) were male and 39(36%) were female. The overall mean age was 69±46.54 months (range: 12-168 months). The mean platelet count was 59.8±46.1/µl (range: 1,000-149,000/µl). Besides, 24 (22.2%) children had mild thrombocytopenia, 34(31.5%) had moderate and 50(46.3 %) had severe thrombocytopenia. The causes of haematological thrombocytopenia in descending order of frequency was acute lymphoblastic leukaemia 17(15.7%), idiopathic thrombocytopenic purpura 10(8.3%) and aplastic anaemia 5(4.6%).
Conclusions: Acute lymphoblastic leukaemia was the commonest cause of haematological thrombocytopenia followed by idiopathic thrombocytopenic purpura and aplastic anaemia.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Assessing the Diagnostic Value of Mean Monocyte Volume and Hematological Parameters in Predicting Dengue Fever: A Cross-Sectional Analysis.
Cureus
December 2024
Department of Hematology, School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, MYS.
Background And Aim: Distinguishing dengue fever (DF) from other viral infections solely based on common presentations poses a challenge. Therefore, there is a pressing need for additional diagnostic parameters that are reliable, swift, and cost-effective. This study aims to provide novel insights into the diagnostic value of hematological parameters, particularly mean monocyte volume (MMV), in predicting DF in Kelantan, Malaysia.
View Article and Find Full Text PDFSuccessful Use of TPO-Receptor Agonist Eltrombopag to Correct Thrombocytopenia for Unrelated-Donor Renal Transplant in an Adolescent with MYH-9-Related Disease.
Pediatr Blood Cancer
January 2025
Department of Pediatrics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Progesterone Regulates Gut Microbiota Mediating Bone Marrow MSCs Injury in ITP Patients during Pregnancy.
J Thromb Haemost
January 2025
Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China; National Clinical Research Center for Hematologic Disease, Beijing, China; Collaborative Innovation Center of Hematology, Peking University, Beijing, China; Clinical Research Center for Hematologic Disease, Beijing, China. Electronic address:
Background: Immune thrombocytopenia during pregnancy (PITP) is the most common cause of platelet reduction in early and mid-pregnancy. However, the pathogenesis of PITP is still unclear.
Objectives: To determine the characteristics of bone marrow mesenchymal stem cells (BM-MSCs) in PITP patients and to explore the associations between metabolites, the gut microbiota, and BM-MSCs in PITP.
Therapeutic potential of roxadustat in immune thrombocytopenia: A Mendelian randomization analysis.
J Thromb Haemost
January 2025
Hematology Department, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Electronic address:
Background: Immune thrombocytopenia (ITP) is characterized by immune-mediated platelet destruction and impaired megakaryocyte maturation. Hypoxia-inducible factor-1 alpha (HIF-1α), pivotal in the development of megakaryocytes and immune regulation, is downregulated in ITP. Roxadustat, which stabilizes HIF-1α, has emerged as a potential therapeutic drug for ITP that acts by enhancing HIF-1α-mediated megakaryocyte development and modulating immune responses.
View Article and Find Full Text PDFLong-term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: A real-world observational study.
Br J Haematol
January 2025
Hematology Department, Beijing Children's Hospital, Hemophilia Comprehensive Care Center, National Center for Children's Health, Capital Medical University, Beijing, China.
Avatrombopag is a newly approved thrombopoietin receptor agonist for second-line treatment of chronic immune thrombocytopenia (ITP) in adults. Our previous study showed its efficacy and safety in a small sample of paediatric ITP patients. However, large samples and long-term data are still lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!